Compare ResMed Inc. (RMD) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Nuscale Power Corporation — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.89B), while Nuscale Power Corporation trades at $10.8 (market cap $4.59B). The key difference: ResMed Inc. is far larger — about 6.9× Nuscale Power Corporation's market cap, and ResMed Inc. pays a 1.19% dividend while Nuscale Power Corporation pays none. Which is the better fit depends on your goals.
| RMD | SMR | |
|---|---|---|
Market Cap | $31.89B | $4.59B |
Sector | Health | Utilities |
52-Week High | $283.28 | $53.43 |
52-Week Low | $182.82 | $7.59 |
Enterprise Value | $31.24B | $3.52B |
Dividend Yield | 1.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
SMR stock surged 15.32% to $11.18, showing strong bullish momentum with technical indicators supporting the uptrend. The company maintains a substantial cash position of $1.9 billion despite significant operating losses and negative profit margins. Recent news highlights NuScale's positioning in the nuclear energy sector, particularly for AI power demands, though the company remains years away from commercial deployment.
The outlook remains speculative with Wall Street divided - 50% of analysts recommend Buy with a $11.25 consensus target. Key risks include cash burn acceleration, lack of firm commercial contracts, and execution challenges in bringing small modular reactors to market. The stock offers high-risk/high-reward potential for investors betting on nuclear energy adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
